Julie Sheppard – författare

Britain’s high street revolution has made retailing one of the most important and dynamic sectorsof the British economy in the last twenty years. It has had an irreversible impact on our towns and cities and, for many people, transformed shopping from an unattractive domestic chore to a pleasurable ‘leisure ‘experience’, offering consumers an everchanging array of ‘disposable dreams’. The resulting ‘retail culture’ is everywhere – it has colonised huge areas of our social life outside the traditional high street, from sporting venues to arts centres, from railway termini to museums. Many see it as the epitome of Thatcher’s Britain, breeding acquisitive individualism and destroying our traditional manufacturing base. Others see it as a potential saviour of an ailing economy.Yet to date there has been no thorough analysis of this all-pervasive phenomenon, from its economic roots to its profound social effects. In Consuming Passion, Carl Gardner and Julie Sheppard have written the first overall study of the ‘retail revolution’ – a controversial and hard-hitting look at where retailing has come from, what it has achieved and where it is going. Key issues such as the role of design, the growth of the supermarket and shopping centre and the poor conditions of retail employment are all minutely examined. The book also discusses the very real pleasures that consumers gain from today’s enhanced shopping experience.The authors take an iconoclastic look at some of the powerful myths that have sprung up around retail: ‘the death of the high street’ scenario; the central role of credit; retailing as a major creator of employment; and the imminent possibility of ‘retail saturation’. A fascinating book for everyone who likes shopping – and even those who hate it.First published 1989.

How do drugs get to the market? What controls are there and what procedures for monitoring their effects? And how adequate are the regulators in protecting public health when new drugs have serious side effects? The Therapeutic Nightmare tells the story of the sleeping pill Halcion - a story which is far from over. First marketed in the 1970s, Halcion has been taken by millions of patients around the world. For many years it has been associated with serious adverse effects such as amnesia, hallucinations, aggression and, in extreme cases, homicide. Thirteen years after its first release, it was banned by the British government. It remains on sale in the United States and many other countries. This book explains why patients have come to be exposed to Halcion's risks and examines the corporate interests of the manufacturers, the professional interests of the scientists and medical researchers and the interests of patients in safe and effective medication. It reveals how these contending forces shape the regulatory decision-making process about drug safety. As the number of new drugs and health products grows, a major challenge facing regulators and the medical profession is how to put the interests of public health decisively and consistently above the commercial interests of the drugs industry, while becoming more accountable to patient and consumer organizations.

How do drugs get to the market? What controls are there and what procedures for monitoring their effects? And how adequate are the regulators in protecting public health when new drugs have serious side effects? The Therapeutic Nightmare tells the story of the sleeping pill Halcion - a story which is far from over. First marketed in the 1970s, Halcion has been taken by millions of patients around the world. For many years it has been associated with serious adverse effects such as amnesia, hallucinations, aggression and, in extreme cases, homicide. Thirteen years after its first release, it was banned by the British government. It remains on sale in the United States and many other countries. This book explains why patients have come to be exposed to Halcion's risks and examines the corporate interests of the manufacturers, the professional interests of the scientists and medical researchers and the interests of patients in safe and effective medication. It reveals how these contending forces shape the regulatory decision-making process about drug safety. As the number of new drugs and health products grows, a major challenge facing regulators and the medical profession is how to put the interests of public health decisively and consistently above the commercial interests of the drugs industry, while becoming more accountable to patient and consumer organizations.